Dr. Pak has been in the Biotechnology field for over three decades. He was formerly associated with Centocor, a top-tier biopharmaceutical company, now a subsidiary of Johnson and Johnson. Dr. Pak holds numerous patents and has published more than seventy articles covering the use of antibodies and small molecules for cancer and cardiovascular diseases.

Dr. Gray has over 30 years experience developing products in the biotech industry. He started out at SmithKline Beckman (now GlaxoSmithKline) and subsequently assumed roles of increasing responsibility at two start-ups, Zynaxis which he co-founded and PTI Research, Inc. He has been involved in radiotracer development for cell death imaging for 10 years at Molecular Targeting Technologies, Inc. He has published 47 papers and holds 6 patents.

Dr. Mattis is a biopharmaceutical executive with more than 30 years experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as VP of Pharmaceutical Development at Centocor. He was instrumental in obtaining US and other market approvals for ReoPro (an anti-platelet drug used in coronary angioplasty), Remicade (for treatment of Crohn's disease and rheumatoid arthritis) and Myoscint (a cardiac imaging agent)

Dr. Silvon is seasoned executive in CRO operations, strategic planning and M&A. He has been creating, fixing and growing most phases of high science, heavily regulated, life sciences service companies for more than 20 years. Palantek, his advisory firm drives planning, operations and growth among research institutions. As VP Global Biopharma Services at Charles River Labs, he integrated 5 sites and established it as a top tier services provider.